GlobeNewswire

Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)

Share
  • Disease control rate of 79% with one complete response

  • Consistent safety and tolerability profile

  • Study continues with topline results expected in H1 2022

Basel, Switzerland, March 24, 2021

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today positive results of a pre-planned interim analysis in cohort 2 of the phase 2 study FIDES-01 (Fibroblast growth factor Inhibition with DErazantinib in Solid tumors), which is assessing the anti-tumor efficacy of the orally administered fibroblast growth factor receptor (FGFR) inhibitor, derazantinib, in patients with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA), a form of bile duct cancer.1 After cohort 1 of the study provided the clinical proof of concept for derazantinib monotherapy in the treatment of iCCA patients with FGFR2 gene fusions, cohort 2 is enrolling iCCA patients with FGFR2 gene mutations or amplifications.2 The efficacy data obtained in the interim analysis met the pre-specified threshold so that the study will proceed to the next stage as planned.

The interim analysis of cohort 2 is based on 14 evaluable patients who had at least one post-baseline tumor assessment. The pre-specified criterion that at least 8 patients met the primary endpoint of obtaining progression-free survival (PFS) of at least 3 months was successfully achieved. The positive interim analysis allows the study to advance to its next stage and enrol a total of 43 patients. As a number of patients are still ongoing with treatment the median PFS was not yet mature at the time of the interim analysis and will be defined at a later time point.

The disease control rate (DCR), reflecting the proportion of patients with a complete or partial response or with stable disease, was 79%, including one patient with a confirmed complete response, one patient with an unconfirmed partial response and nine patients with a best response of stable disease at the time when the interim analysis was conducted.

The observed safety and tolerability is consistent with the profile reported for cohort 1.

Dr. Marc Engelhardt, Chief Medical Officer, said: “We are very pleased with the positive interim results for this cohort of iCCA patients with FGFR2 gene mutations or amplifications. The clinical benefit with derazantinib is similar to that reported for iCCA patients with FGFR2 gene fusions earlier this year. This supports the relevance of derazantinib in a group of patients with iCCA where there has been very limited clinical evidence of successful treatment with other FGFR inhibitors and confirms the broad potential of derazantinib as a monotherapy for the treatment of iCCA patients with diverse FGFR2 genetic aberrations. This outcome is very encouraging and further strengthens the evidence for the differentiation of derazantinib versus other FGFR inhibitors both from the efficacy and safety perspective. We are now progressing the study to the next stage and expect topline results for cohort 2 in the first half of 2022.”

About derazantinib

Derazantinib is an investigational orally administered small-molecule FGFR inhibitor with strong activity against FGFR1, 2, and 3.3 FGFR kinases are key drivers of cell proliferation, differentiation and migration. FGFR genetic aberrations, e.g. gene fusions, mutations or amplifications, have been identified as potentially important therapeutic targets for various cancers, including intrahepatic cholangiocarcinoma (iCCA), urothelial, breast, gastric and lung cancers.4 In these cancers, FGFR genetic aberrations are found in a range of 5% to 30%.5
Derazantinib also inhibits the colony-stimulating-factor-1-receptor kinase (CSF1R).3, 6 CSF1R-mediated signaling is important for the maintenance of tumor-promoting macrophages and therefore has been identified as a potential target for anti-cancer drugs.7 Pre-clinical data has shown that tumor macrophage depletion through CSF1R blockade renders tumors more responsive to T-cell checkpoint immunotherapy, including approaches targeting PD-L1/PD-1.8,9
Derazantinib has demonstrated antitumor activity and a manageable safety profile in a previous biomarker-driven phase 1/2 study in iCCA patients,10 and has received U.S. and EU orphan drug designation for iCCA. Basilea is currently conducting three clinical studies with derazantinib. The first study, FIDES-01, is a phase 2 study in patients with inoperable or advanced iCCA. It comprises one cohort of patients with FGFR2 gene fusions and another cohort of patients with mutations or amplifications.1 The second study, FIDES-02, is a phase 1/2 study evaluating derazantinib alone and in combination with Roche's PD-L1 checkpoint inhibitor, atezolizumab, in patients with advanced urothelial cancer, including metastatic, or recurrent surgically unresectable disease, expressing FGFR genetic aberrations.11 The third study, FIDES-03, is a phase 1/2 study evaluating derazantinib alone and in combination with Lilly’s anti-VEGFR2 antibody ramucirumab and paclitaxel, or with Roche’s PD-L1 checkpoint inhibitor atezolizumab, in patients with advanced gastric cancer with FGFR genetic aberrations.12 Basilea has in-licensed derazantinib from ArQule Inc., a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

About intrahepatic cholangiocarcinoma

Intrahepatic cholangiocarcinoma (iCCA) is a cancer originating from the biliary system. The age-adjusted incidence rate of iCCA in the United States has been increasing over the past decade and is currently estimated to be approximately 1.2 per 100,000.13 Patients are often diagnosed with advanced or metastatic disease that cannot be surgically removed. Current first-line standard of care is the chemotherapy combination of gemcitabine and platinum-derived agents. The prognosis for patients with advanced disease is poor, with a median survival of less than one year.14

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Derazantinib and its uses are investigational and have not been approved by a regulatory authority for any use. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in nonclinical/preclinical studies to humans is currently being evaluated.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone+41 61 606 1102
E-mailmedia_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

References

  1. FIDES-01: ClinicalTrials.gov identifier: NCT03230318
  2. Topline results of cohort 1 of the FIDES-01 study were published on February 10, 2021 (see press release)
  3. T. G. Hall, Y. Yu, S. Eathiraj et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS ONE 2016, 11 (9), e0162594
  4. R. Porta, R. Borea, A. Coelho et al. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Critical Reviews in Oncology/Hematology 2017 (113), 256-267
  5. T. Helsten, S. Elkin, E. Arthur et al. The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer Research 2016 (22), 259-267
  6. P. McSheehy, F. Bachmann, N. Forster-Gross et al. Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer. Molecular Cancer Therapeutics 2019 (18), 12 supplement, pp. LB-C12
  7. M. A. Cannarile, M. Weisser, W. Jacob et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy of Cancer 2017, 5:53
  8. Y. Zhu, B. L. Knolhoff, M. A. Meyer et al. CSF1/CSF1R Blockade reprograms tumor-infiltrating macrophages and improves response to T cell checkpoint immunotherapy in pancreatic cancer models. Cancer Research 2014 (74), 5057-5069
  9. E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proceedings of the National Academy of Science of the United States of America 2018 (115), E4041-E4050
  10. V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120), 165-171. ClinicalTrials.gov identifier: NCT01752920
  11. FIDES-02: ClinicalTrials.gov identifier: NCT04045613
  12. FIDES-03: ClinicalTrials.gov identifier: NCT04604132
  13. S. K. Saha, A. X. Zhu, C. S. Fuchs et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. The Oncologist 2016 (21), 594-599
  14. A. Lamarca, D. H. Palmer, H. S. Wasa et al. ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. Journal of Clinical Oncology 2019 (37), supplement, abstract 4003 

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

NEP’s Solution for Aurora, North One and Extreme E Tests Its Metal In Some of the World’s Harshest Conditions13.4.2021 19:21:56 CEST | Press release

SHOWCASING CUTTING EDGE TECHNOLOGY & SUSTAINABILITY WORKING TOGETHER LONDON, April 13, 2021 (GLOBE NEWSWIRE) -- Last weekend marked the first event for Extreme E, a new all-electric off-road racing series designed to highlight the climate crisis. NEP Group, the leading technical partner for content producers around the globe, worked with Extreme E and host broadcaster Aurora Media Worldwide and North One, to create a cutting-edge, sustainable broadcast solution that brought the first race, in AlUla, Saudi Arabia, into homes in 180 countries around the globe. Designed to mirror Extreme E’s goals of marrying the latest technology with sustainability and building solutions to meet the rigors of the world’s harshest conditions, NEP’s innovative broadcast services will be used by Aurora and North One at races in Senegal, Greenland, Brazil and Patagonia as the series continues. NEP’s complete end-to-end broadcast package includes a custom IP flypack, remote production solutions, crewing, sat

Annual General Meeting 2021: Tecan shareholders endorse all motions proposed by the Board of Directors13.4.2021 17:45:00 CEST | Press release

Votes cast exclusively through the independent proxy in line with COVID-19 Ordinance 3 of the Swiss government to combat the pandemicIncrease in the dividend from CHF 2.20 to CHF 2.30 per share Lukas Braunschweiler, Heinrich Fischer, Oliver Fetzer, Karen Huebscher, Christa Kreuzburg and Daniel R. Marshak re-elected as members of the Board of DirectorsLukas Braunschweiler confirmed by shareholders as Chairman of the BoardChrista Kreuzburg, Oliver Fetzer and Daniel R. Marshak confirmed as members of the Compensation CommitteeAll proposals relating to compensation approved Männedorf, Switzerland, April 13, 2021 – The Annual General Meeting of the Tecan Group (SIX Swiss Exchange: TECN) endorsed all motions proposed by the Board of Directors on April 13, 2021. The Annual General Meeting was held at the headquarters of the company, without personal attendance by shareholders. Voting rights could only be exercised through the independent proxy in line with the Federal Act on the Statutory Pri

Stockwik offentliggör avsikt att genomföra en riktad nyemission om upp till 1 026 055 nya aktier13.4.2021 17:31:00 CEST | Pressemelding

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDANT OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION INTE SKULLE VARA FÖRENLIG MED TILLÄMPLIGA FÖRESKRIFTER ELLER KRÄVA REGISTRERING ELLER LIKNANDE ÅTGÄRDER. VÄNLIGEN SE VIKTIG INFORMATION I SLUTET AV PRESSMEDDELANDET. Stockwik Förvaltning AB (publ) (”Stockwik” eller ”Bolaget”) offentliggör avsikt att genomföra en riktad nyemission om upp till 1 026 055 nya aktier till svenska och internationella institutionella investerare (den ”Riktade Nyemissionen”). Bolaget avser att genomföra den Riktade Nyemissionen med avvikelse från aktieägarnas företrädesrätt med stöd av bemyndigandet från årsstämman den 8 maj 2020. Stockwik har gett Pareto Securities AB (”Pareto Securities”) i uppdrag att utreda förutsättningarna för att genomföra den Riktade Nyemissionen genom

Stockwik announces intention to carry out a directed new share issue of up to 1,026,055 new shares13.4.2021 17:31:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Stockwik Förvaltning AB (publ) (”Stockwik” or the ”Company”) hereby announces intention to carry out a directed new share issue of up to 1,026,055 new shares directed to Swedish and international institutional investors (the “Directed New Share Issue”). The Company intends to carry out the Directed New Share Issue with deviation from the shareholders' preferential rights pursuant to the authorization granted by the annual general meeting on 8 May 2020. Stockwik has engaged Pareto Securities AB (“Pareto Securities”) to investigate the conditions to carry out the Directed New Shar

Norsk Hydro: Innkalling til generalforsamling 202113.4.2021 16:27:22 CEST | Pressemelding

Aksjeeierne i Norsk Hydro ASA innkalles til ordinær Generalforsamling torsdag 6. mai 2021 kl. 10:00. Generalforsamlingen vil i år gjennomføres digitalt med elektronisk stemmegivning som følge av Covid-19 situasjonen. Se vedlagt guide for online deltakelse. Det er også mulig å forhåndsstemme eller gi fullmakt før møtet. Fullstendig innkalling, agenda og vedlegg er vedlagt. Alle relevante dokumenter ligger på www.hydro.com/generalforsamling Investorkontakt Line Haugetraa +47 41406376 Line.haugetraa@hydro.com Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg Arsberetning og arsregnskap 2020Guide for digital deltakelseHydros lonnspolitikkInnkalling til ordinaer generalforsamling 2021Innstilling fra Valgkomiteen 2021Moteseddel

Norsk Hydro: Notice of Annual General Meeting 202113.4.2021 16:27:22 CEST | Press release

Notice is given that the Annual General Meeting of Norsk Hydro ASA will be held on Thursday 6 May 2021 at 10:00 (CEST). Please be informed that the Annual General Meeting will be held as a digital meeting with electronic voting due to the Covid-19 situation. Please refer to the attached guide for online participation. It is also possible to vote in advance or attend the meeting by proxy. The full notice, agenda and appendices are attached. All relevant documents can be found on www.hydro.com/generalmeeting Investor contact: Line Haugetraa +47 41406376 Line.haugetraa@hydro.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments Financial Statements and Board of Directors report 2020Guideline for online participationHydro remuneration policyNotice of General Meeting 2021Recommendation from the Nomination Committee 2021Voting instructions

Kallelse till årsstämma i Stockwik Förvaltning AB (publ)13.4.2021 16:00:00 CEST | Pressemelding

Aktieägarna i Stockwik Förvaltning AB (publ), org. nr 556294-7845, kallas härmed till årsstämma fredagen den 14 maj 2021 kl. 10:00. Mot bakgrund av risken för spridning av Covid-19 och myndigheternas föreskrifter och råd om undvikande av sammankomster har styrelsen med stöd av tillfälliga lagregler beslutat att årsstämman ska genomföras utan fysisk närvaro genom att aktieägare utövar sin rösträtt endast genom poströstning. FÖRUTSÄTTNINGAR FÖR DELTAGANDE Den som önskar att genom poströstning delta i årsstämman ska dels vara upptagen i den av Euroclear Sweden AB framställda aktieboken per onsdagen den 5 maj 2021, dels ha anmält sitt deltagande genom att avge sin poströst i enlighet med anvisning under rubriken POSTRÖSTNING nedan så att poströsten är bolaget tillhanda senast onsdagen den 12 maj 2021. För att ha rätt att delta i årsstämman måste en aktieägare som låtit förvaltarregistrera sina aktier, förutom att anmäla sig till årsstämman genom att avge sin poströst, låta registrera aktie